Gastrointestinal Stromal Tumors Clinical Trial
Official title:
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore.
To review the characteristics and treatment of gastrointestinal tumours at the two tertiary centres in Singapore
A retrospective clinical records review of patients diagnosed with gastrointestinal stromal
tumour (GIST) in the two tertiary centres in Singapore i.e. Singapore General Hospital and
National University Hospital.
Gastrointestinal tumours are the most common soft-tissue tumours of the gastrointestinal
tracts. Remarkable progress has been made during the last several years in the diagnosis and
treatment of GIST. Understanding of the molecular pathogenesis of GIST which is linked to
deregulated KIT tyrosine-kinase activity has improved diagnosis, such that GIST is now more
frequently and specifically identified. More importantly, systemic tyrosine kinase inhibitor,
imatinib, has been used successfully in the treatment of GIST patients with advanced or
unresectable disease.
GIST has been reviewed in the Western literature but there is a lack of Asian data. The
review will help us to better understand the disease in our population.Furthermore we will
also examine several unresolved issues in the Western literature by looking into our local
data. These include required duration of imatinib therapy, role of imatinib in the adjuvant
setting (application of chemotherapy after macroscopically complete removal of tumour) and
role of combination therapies.
The medical records of all patients diagnosed with the disease at the two centres will be
reviewed.
Analysis of the results aims to:
1. to compare the characteristics of the GIST (epidemiology, site, morphology,
immunohistochemistry profile) in our centres compared to the well-published literature.
2. to compare the treatment regimen and results of our centres compared to others
3. to review the role of chemotherapy in the adjuvant settings in the centres.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05385549 -
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
|
Phase 2 | |
| Recruiting |
NCT05905887 -
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
|
Phase 2 | |
| Completed |
NCT01933958 -
Regorafenib Post-marketing Surveillance in Japan
|
||
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Completed |
NCT01440959 -
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
|
Phase 2 | |
| Completed |
NCT00718562 -
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
|
Phase 2 | |
| Completed |
NCT00385203 -
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
|
Phase 2 | |
| Completed |
NCT00137449 -
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
|
Phase 2 | |
| Completed |
NCT00237172 -
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
|
Phase 2 | |
| Terminated |
NCT04409223 -
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
|
Phase 3 | |
| Active, not recruiting |
NCT03556384 -
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
| Recruiting |
NCT04106024 -
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
|
Phase 2 | |
| Completed |
NCT02171286 -
The Oncopanel Pilot (TOP) Study
|
N/A | |
| Completed |
NCT01114087 -
Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility
|
N/A | |
| Recruiting |
NCT05366816 -
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
|
Phase 2 | |
| Recruiting |
NCT03602092 -
Observational Registry Data on GIST Patients
|
||
| Recruiting |
NCT05197933 -
Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
|
N/A | |
| Completed |
NCT02931929 -
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05080621 -
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
|
Phase 1/Phase 2 | |
| Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 |